Genocea Biosciences Inc (GNCA.OQ)
12 Dec 2017
Thu, Nov 2 2017
* Genocea biosciences - expects existing cash and cash equivalents sufficient to support operating expenses and capital expenditure into middle of 2018
BRIEF-Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines
* Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines
* Genocea Biosciences reports second quarter 2017 financial results
- Genocea Biosciences (GNCA) Presents At Stifel 2017 Healthcare Conference - Slideshow
- Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2017 Results - Earnings Call Transcript
- Move Over Yellen! It's Tax Cut Time!
- Genocea Biosciences (GNCA) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
- Biotech Forum Daily Digest: Still Gains Ahead For Dynavax?
- Russell 3000 Stock Anomaly: 10 Stocks To Watch